AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19139424 — intervention group
Group type: COMPARATOR
Intervention: Mitomycin-based therapy
Number of subjects: 644
Study 19139424 — intervention group
Group type: EXPERIMENTAL
Intervention: Large tumor diameter (> 5 cm)
Number of subjects: 644
Study 19139424 — intervention group
Group type: EXPERIMENTAL
Intervention: Node-positive cancer
Number of subjects: 644
Study 19139424 — intervention group
Group type: EXPERIMENTAL
Intervention: Male sex
Number of subjects: 644
Study 18077833 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-session intervention based on motivational interviewing and cognitive-behavioral skills building
Number of subjects: 143
Study 18077833 — intervention group
Group type: COMPARATOR
Intervention: Time- and content-equivalent educational condition
Number of subjects: 143
Study 15528874 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination treatment with losartan and trandolapril
Number of subjects: 92
Study 15528874 — intervention group
Group type: COMPARATOR
Intervention: Losartan
Number of subjects: 92
Study 15528874 — intervention group
Group type: COMPARATOR
Intervention: Trandolapril
Number of subjects: 92
Study 15463826 — intervention group
Group type: EXPERIMENTAL
Intervention: Induced sputum (IS)
Number of subjects: 31
Study 15463826 — intervention group
Group type: COMPARATOR
Intervention: Bronchoalveolar lavage (BAL)
Number of subjects: 31
Study 9578230 — intervention group
Group type: EXPERIMENTAL
Intervention: Fittydent I
Number of subjects: 32
Study 9578230 — intervention group
Group type: EXPERIMENTAL
Intervention: Fittydent II
Number of subjects: 32
Study 9578230 — intervention group
Group type: COMPARATOR
Intervention: Protefix
Number of subjects: 32
Study 9578230 — intervention group
Group type: COMPARATOR
Intervention: Seabond
Number of subjects: 32
Study 7713830 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg)
Number of subjects: 12
Study 7713830 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 7713830 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 12
Study 7713830 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol and Placebo
Number of subjects: 12
Study 2694142 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlortenoxicam 4 mg
Number of subjects: 0
Study 2694142 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin 50 mg
Number of subjects: 0
Study 2694142 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 411434 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose insulin infusion at the rate of 6 units per hour
Number of subjects: 0
Study 411434 — intervention group
Group type: COMPARATOR
Intervention: High-dose, intermittent subcutaneously administered insulin
Number of subjects: 0
Study 31024649 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound guidance (USG)
Number of subjects: 412
Study 31024649 — intervention group
Group type: COMPARATOR
Intervention: Traditional blind palpation (TBP)
Number of subjects: 412
Study 28586395 — intervention group
Group type: EXPERIMENTAL
Intervention: CTCs with strong HER2 staining
Number of subjects: 642
Study 28586395 — intervention group
Group type: EXPERIMENTAL
Intervention: CTCs with negative HER2 staining
Number of subjects: 642
Study 28586395 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of HER2-positive CTCs
Number of subjects: 642
Study 28586395 — intervention group
Group type: EXPERIMENTAL
Intervention: Within-sample variation in HER2 status of CTCs
Number of subjects: 642
Study 28586395 — intervention group
Group type: COMPARATOR
Intervention: Overall association of HER2-positive CTCs with tumor characteristics
Number of subjects: 642
Study 26474517 — intervention group
Group type: EXPERIMENTAL
Intervention: Cediranib 20 mg orally once daily until disease progression
Number of subjects: 69
Study 26474517 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 69
Study 26474517 — intervention group
Group type: EXPERIMENTAL
Intervention: Cediranib
Number of subjects: 69
Study 23815798 — intervention group
Group type: EXPERIMENTAL
Intervention: Prothrombin complex concentrate administration prior to surgery
Number of subjects: 0
Study 23815798 — intervention group
Group type: COMPARATOR
Intervention: Placebo administration prior to surgery
Number of subjects: 0
Study 21794173 — intervention group
Group type: EXPERIMENTAL
Intervention: Formal workshop in EBM literature searching skills
Number of subjects: 0
Study 21794173 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 19341448 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening mammography
Number of subjects: 1000
Study 19341448 — intervention group
Group type: EXPERIMENTAL
Intervention: Single screening mammogram
Number of subjects: 1000
Study 19341448 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated screening starting at age 50
Number of subjects: 1000
Study 19341448 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening at age 40
Number of subjects: 1000
Study 19341448 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening at age 50
Number of subjects: 1000
Study 19341448 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening at age 65
Number of subjects: 1000
Study 16488958 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined photodynamic therapy (PDT) with intravitreal triamcinolone (IVTA)
Number of subjects: 48
Study 16488958 — intervention group
Group type: COMPARATOR
Intervention: PDT monotherapy
Number of subjects: 48
Study 15285023 — intervention group
Group type: EXPERIMENTAL
Intervention: DA-9601 180 mg
Number of subjects: 512
Study 15285023 — intervention group
Group type: EXPERIMENTAL
Intervention: DA-9601 360 mg
Number of subjects: 512
Study 15285023 — intervention group
Group type: COMPARATOR
Intervention: Cetraxate 600 mg
Number of subjects: 512
Study 11127783 — intervention group
Group type: EXPERIMENTAL
Intervention: Complementary Medicine (CM)
Number of subjects: 0
Study 11127783 — intervention group
Group type: COMPARATOR
Intervention: Quality profiles comparison
Number of subjects: 0
Study 11127783 — intervention group
Group type: EXPERIMENTAL
Intervention: Randomized Controlled Trials (RCTs)
Number of subjects: 0
Study 9269642 — intervention group
Group type: EXPERIMENTAL
Intervention: RenaGel 1 g
Number of subjects: 24
Study 9269642 — intervention group
Group type: EXPERIMENTAL
Intervention: RenaGel 2.5 g
Number of subjects: 24
Study 9269642 — intervention group
Group type: EXPERIMENTAL
Intervention: RenaGel 5 g
Number of subjects: 24
Study 9269642 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 1586329 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous Syntocinon
Number of subjects: 106
Study 1586329 — intervention group
Group type: COMPARATOR
Intervention: Vaginal prostaglandin E2 pessaries
Number of subjects: 106
Study 3517644 — intervention group
Group type: EXPERIMENTAL
Intervention: Tolazamide
Number of subjects: 8
Study 3517644 — intervention group
Group type: EXPERIMENTAL
Intervention: Exogenous insulin
Number of subjects: 8
Study 31597517 — intervention group
Group type: EXPERIMENTAL
Intervention: Trial volunteering
Number of subjects: 445
Study 31597517 — intervention group
Group type: COMPARATOR
Intervention: Usual activities (Control)
Number of subjects: 445
Study 29996542 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression and anxiety prevention program 'Een Sprong Vooruit' (A Leap Forward)
Number of subjects: 142
Study 29996542 — intervention group
Group type: COMPARATOR
Intervention: Control condition
Number of subjects: 142
Study 28031607 — intervention group
Group type: EXPERIMENTAL
Intervention: Flipped classroom with Poll Everywhere ARS
Number of subjects: 112
Study 25281655 — intervention group
Group type: EXPERIMENTAL
Intervention: Nesiritide
Number of subjects: 7141
Study 22369603 — intervention group
Group type: EXPERIMENTAL
Intervention: Early external cephalic version at 34(0/7) to 35(6/7) weeks
Number of subjects: 1543
Study 22369603 — intervention group
Group type: COMPARATOR
Intervention: Traditional timing of external cephalic version (greater than 37 weeks)
Number of subjects: 1543
Study 20213585 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional regimen (13 cycles of 21+7 days)
Number of subjects: 59
Study 20213585 — intervention group
Group type: EXPERIMENTAL
Intervention: Extended-cycle regimen (4 cycles of 84+7 days)
Number of subjects: 59
Study 18373318 — intervention group
Group type: EXPERIMENTAL
Intervention: MCP treatment for 30 minutes during eight days
Number of subjects: 55
Study 18373318 — intervention group
Group type: COMPARATOR
Intervention: No MCP treatment
Number of subjects: 55
Study 16032749 — intervention group
Group type: EXPERIMENTAL
Intervention: Pegylated interferon plus ribavirin for 48 weeks
Number of subjects: 28
Study 12151922 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard hospital blankets (set point, 38 degrees C)
Number of subjects: 83
Study 12151922 — intervention group
Group type: COMPARATOR
Intervention: Commercial Bair Hugger blanket (control group, set point, 43 degrees C)
Number of subjects: 83
Study 12151922 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard hospital blankets
Number of subjects: 83
Study 12151922 — intervention group
Group type: COMPARATOR
Intervention: Commercial Bair Hugger blanket
Number of subjects: 83
Study 12024416 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib
Number of subjects: 0
Study 12024416 — intervention group
Group type: EXPERIMENTAL
Intervention: Rofecoxib
Number of subjects: 0
Study 12024416 — intervention group
Group type: COMPARATOR
Intervention: NSAIDs
Number of subjects: 0
Study 12024416 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8655293 — intervention group
Group type: EXPERIMENTAL
Intervention: Pentoxifylline at a dose of 800 mg thrice daily
Number of subjects: 6
Study 8655293 — intervention group
Group type: COMPARATOR
Intervention: Control period (no treatment)
Number of subjects: 6
Study 2140763 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenylephrine HCl, 2.5%
Number of subjects: 7
Study 2140763 — intervention group
Group type: EXPERIMENTAL
Intervention: Thymoxamine HCl, 0.5%
Number of subjects: 7
Study 2140763 — intervention group
Group type: COMPARATOR
Intervention: Saline control
Number of subjects: 7
Study 435053 — intervention group
Group type: EXPERIMENTAL
Intervention: Albumin therapy
Number of subjects: 94
Study 435053 — intervention group
Group type: COMPARATOR
Intervention: Control (no albumin therapy)
Number of subjects: 94
Study 6312460 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 g cefotiam twice daily for 10 days
Number of subjects: 35
Study 6312460 — intervention group
Group type: COMPARATOR
Intervention: 1 g cephalothin 4-times daily for 10 days
Number of subjects: 35
Study 30778742 — intervention group
Group type: EXPERIMENTAL
Intervention: Hospital-based work support intervention
Number of subjects: 106
Study 30778742 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 106
Study 30778742 — intervention group
Group type: EXPERIMENTAL
Intervention: Receiving chemotherapy
Number of subjects: 106
Study 30778742 — intervention group
Group type: EXPERIMENTAL
Intervention: Low level of education
Number of subjects: 106
Study 30778742 — intervention group
Group type: EXPERIMENTAL
Intervention: Low work ability
Number of subjects: 106
Study 30428909 — intervention group
Group type: EXPERIMENTAL
Intervention: Active Interpretation Bias Training (IBT)
Number of subjects: 40
Study 30428909 — intervention group
Group type: COMPARATOR
Intervention: Sham training (Control)
Number of subjects: 40
Study 30428909 — intervention group
Group type: EXPERIMENTAL
Intervention: Active IBT
Number of subjects: 40
Study 26475499 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.12 % CHX + 0.05 % CPC (Perio-Aid® Treatment alcohol-free)
Number of subjects: 150
Study 26475499 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.03 % CHX + 0.05 % CPC new test formulation
Number of subjects: 150
Study 26475499 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 150
Study 24638976 — intervention group
Group type: EXPERIMENTAL
Intervention: Carum carvi extract (CAE) 30ml/day
Number of subjects: 70
Study 24638976 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 22179530 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 6206
Study 22179530 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel
Number of subjects: 6206
Study 19537926 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG body surface mapping (BSM) parameters in DM1 patients with AN
Number of subjects: 54
Study 19537926 — intervention group
Group type: EXPERIMENTAL
Intervention: Classic 12-lead ECG in DM1 patients
Number of subjects: 54
Study 19537926 — intervention group
Group type: EXPERIMENTAL
Intervention: QT duration measured in 82 leads of thorax in DM1 patients
Number of subjects: 54
Study 19537926 — intervention group
Group type: EXPERIMENTAL
Intervention: ECG BSM method
Number of subjects: 54
Study 19537926 — intervention group
Group type: COMPARATOR
Intervention: ECG BSM parameters in DM1 patients without AN
Number of subjects: 54
Study 18093490 — intervention group
Group type: EXPERIMENTAL
Intervention: Centralized telephone intervention by trained nurses
Number of subjects: 1518
Study 18093490 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 1518
Study 16144891 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 1744
Study 11872656 — intervention group
Group type: EXPERIMENTAL
Intervention: Increased plasma amino acids (approximately 4.6 mmol/l)
Number of subjects: 7
Study 9457223 — intervention group
Group type: EXPERIMENTAL
Intervention: 123I-labeled MIBG
Number of subjects: 58
Study 9457223 — intervention group
Group type: EXPERIMENTAL
Intervention: 125I-labeled MIBG
Number of subjects: 58
Study 7871405 — intervention group
Group type: EXPERIMENTAL
Intervention: SAKK (HD-4)
Number of subjects: 113
Study 7871405 — intervention group
Group type: COMPARATOR
Intervention: DHSG (HD-4)
Number of subjects: 113
Study 7871405 — intervention group
Group type: EXPERIMENTAL
Intervention: SAKK (HD-5)
Number of subjects: 113
Study 7871405 — intervention group
Group type: COMPARATOR
Intervention: DHSG (HD-5)
Number of subjects: 113
Study 7871405 — intervention group
Group type: EXPERIMENTAL
Intervention: SAKK (HD-6)
Number of subjects: 113
Study 7871405 — intervention group
Group type: COMPARATOR
Intervention: DHSG (HD-6)
Number of subjects: 113
Study 2105049 — intervention group
Group type: EXPERIMENTAL
Intervention: Encainide
Number of subjects: 725
Study 2105049 — intervention group
Group type: EXPERIMENTAL
Intervention: Flecainide
Number of subjects: 725
Study 2105049 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 725
Study 523673 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E2 (PGE2) administered via tablets, gel, and pessary bases
Number of subjects: 27
Study 31124275 — intervention group
Group type: EXPERIMENTAL
Intervention: Lobectomy
Number of subjects: 10000
Study 31124275 — intervention group
Group type: COMPARATOR
Intervention: Stereotactic Ablative Radiotherapy (SABR)
Number of subjects: 10000
Study 27681813 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-articular injections of hyaluronic acid 1.6% (group A)
Number of subjects: 60
Study 27681813 — intervention group
Group type: EXPERIMENTAL
Intervention: Syalox 300 Plus® (hyaluronic acid 300 mg + Boswellia serrata extract 100 mg) for 20 days followed by Syalox 150® (hyaluronic acid 150 mg) for another 20 days (group B)
Number of subjects: 60
Study 25662958 — intervention group
Group type: EXPERIMENTAL
Intervention: OPCAB no-touch technique
Number of subjects: 400
Study 23807157 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse-peer model
Number of subjects: 85
Study 23807157 — intervention group
Group type: COMPARATOR
Intervention: Doctor-counselor model
Number of subjects: 85
Study 21075370 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy
Number of subjects: 8
Study 19438847 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose furosemide (250-1000 mg/bid i.v.) plus hypertonic saline solutions (150 mL H(2)O with NaCl 1.4-4.6%)
Number of subjects: 84
Study 19438847 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose furosemide plus hypertonic saline solutions
Number of subjects: 84
Study 19438847 — intervention group
Group type: COMPARATOR
Intervention: Repeated paracentesis and standard diuretic schedule
Number of subjects: 84
Study 17974118 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate nonocclusal loading
Number of subjects: 52
Study 17974118 — intervention group
Group type: COMPARATOR
Intervention: Early loading
Number of subjects: 52
Study 15470832 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste containing 1450 ppm F (n=218)
Number of subjects: 703
Study 15470832 — intervention group
Group type: EXPERIMENTAL
Intervention: Toothpaste containing 440 ppm F (n=226)
Number of subjects: 703
Study 15470832 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=259)
Number of subjects: 703
Study 10886488 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin (10 microg intravenously)
Number of subjects: 23
Study 10886488 — intervention group
Group type: EXPERIMENTAL
Intervention: Hexarelin (2 microgram kg‐1 intravenously)
Number of subjects: 23
Study 10886488 — intervention group
Group type: EXPERIMENTAL
Intervention: Dexamethasone (1 mg) suppression test
Number of subjects: 23
Study 10886488 — intervention group
Group type: EXPERIMENTAL
Intervention: Desmopressin and Hexarelin tests
Number of subjects: 23
Study 10886488 — intervention group
Group type: COMPARATOR
Intervention: Hexarelin
Number of subjects: 23
Study 10886488 — intervention group
Group type: COMPARATOR
Intervention: Desmopressin
Number of subjects: 23
Study 9291171 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous immunoglobulin (IVIG) treatment
Number of subjects: 0
Study 9291171 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 8346832 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroprusside and diltiazem (bolus of 80 micrograms/kg with two consecutive infusions of 4.5 micrograms.kg‐1.min‐1 during the first 30 min and then 1.3 micrograms.kg‐1.min‐1)
Number of subjects: 20
Study 8346832 — intervention group
Group type: COMPARATOR
Intervention: Nitroprusside alone
Number of subjects: 20
Study 8346832 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroprusside and diltiazem
Number of subjects: 20
Study 3567466 — intervention group
Group type: EXPERIMENTAL
Intervention: CT with 16.25 g iodine contrast medium
Number of subjects: 45
Study 3567466 — intervention group
Group type: EXPERIMENTAL
Intervention: CT with 32.5 g iodine contrast medium
Number of subjects: 45
Study 3567466 — intervention group
Group type: COMPARATOR
Intervention: CT without intravenous contrast medium
Number of subjects: 45
Study 31048295 — intervention group
Group type: COMPARATOR
Intervention: Epidural lidocaine alone
Number of subjects: 350
Study 31048295 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural corticosteroid and lidocaine
Number of subjects: 350
Study 29798249 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient controlled intravenous analgesia (Group A)
Number of subjects: 124
Study 29798249 — intervention group
Group type: COMPARATOR
Intervention: Ibuprofen (5 mg/kg/sub) (Group B)
Number of subjects: 124
Study 23146277 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic conversation intervention (2-5 sessions with a nurse)
Number of subjects: 136
Study 23146277 — intervention group
Group type: COMPARATOR
Intervention: Standard family nursing care (control group)
Number of subjects: 136
Study 21908460 — intervention group
Group type: EXPERIMENTAL
Intervention: Abrupt quitting with nicotine lozenge, quit date set between 1 and 3 weeks after study onset.
Number of subjects: 0
Study 21908460 — intervention group
Group type: COMPARATOR
Intervention: Gradual quitting with nicotine lozenge, quit date set between 3 and 5 weeks after study entry.
Number of subjects: 0
Study 21908460 — intervention group
Group type: EXPERIMENTAL
Intervention: Quit after planned quit date.
Number of subjects: 0
Study 19196319 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.0% amine fluoride fluid
Number of subjects: 0
Study 19196319 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5% amine fluoride fluid
Number of subjects: 0
Study 19196319 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 16488057 — intervention group
Group type: EXPERIMENTAL
Intervention: 2‐L pulse lavage normal saline washout
Number of subjects: 0
Study 16488057 — intervention group
Group type: COMPARATOR
Intervention: 2‐L normal saline washout via a jug or a syringe
Number of subjects: 0
Study 15615236 — intervention group
Group type: EXPERIMENTAL
Intervention: Brochure provided to patients (case group)
Number of subjects: 54
Study 15615236 — intervention group
Group type: COMPARATOR
Intervention: No brochure provided (control group)
Number of subjects: 54
Study 11918093 — intervention group
Group type: EXPERIMENTAL
Intervention: Virtual reality training with conflicting visual-vestibular stimulation (VVS) for 45 minutes
Number of subjects: 24
Study 8856712 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine (low dose)
Number of subjects: 10
Study 8856712 — intervention group
Group type: EXPERIMENTAL
Intervention: Adenosine (increasing doses)
Number of subjects: 10
Study 8856712 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 1727765 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate refeeding (regular diet immediately)
Number of subjects: 258
Study 1727765 — intervention group
Group type: COMPARATOR
Intervention: Delayed refeeding (nothing by mouth for 36 hours, then clear liquids for 12 hours, and a regular diet thereafter)
Number of subjects: 258
Study 1727765 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate refeeding
Number of subjects: 258
Study 1727765 — intervention group
Group type: COMPARATOR
Intervention: Delayed refeeding
Number of subjects: 258
Study 1727765 — intervention group
Group type: EXPERIMENTAL
Intervention: Rebleeding in patients with clean-based ulcers
Number of subjects: 258
Study 1727765 — intervention group
Group type: EXPERIMENTAL
Intervention: Rebleeding in patients with ulcers with spots
Number of subjects: 258
Study 1727765 — intervention group
Group type: EXPERIMENTAL
Intervention: Rebleeding in patients with ulcers with clots
Number of subjects: 258
Study 1727765 — intervention group
Group type: EXPERIMENTAL
Intervention: Rebleeding in patients with Mallory-Weiss tears
Number of subjects: 258
Study 6094373 — intervention group
Group type: EXPERIMENTAL
Intervention: NaHCO3 (0.2 g/kg B.W.)
Number of subjects: 11
Study 6094373 — intervention group
Group type: EXPERIMENTAL
Intervention: NaHCO3
Number of subjects: 11
Study 6094373 — intervention group
Group type: COMPARATOR
Intervention: NaCl (placebo)
Number of subjects: 11